Select Page ::

biochemical diagnostic reagent Market Report Examines Business Opportunity and Worldwide Scope by Forecast 2021 to 2026 The Courier – The Courier

Posted on June 7, 2021 by Danzig

A new report titled, Global biochemical diagnostic reagent Market has been added into its vast repository by Straits Research. The report analyzes and estimates the biochemical diagnostic reagent market on a global, regional, and country level. The report offers data of previous years along with an in-depth analysis from 2017 to 2022 on the basis of revenue (USD Billion). Besides, the report offers a comprehensive analysis about the factors driving and restraining the growth of the market coupled with the impact they have on the demand over the forecast period. In addition, the report includes the study of lucrative opportunities available in the biochemical diagnostic reagent market on a global level.

To get SAMPLE of the report, please click:https://marketstrides.com/request-sample/biochemical diagnostic reagent

TheMajorPlayers Covered in this Report:RocheBeijing Strong BiotechnologiesRandoxSiemens HealthineersFosunPharmaBeckman CoulterSysmexBeijing Leadman BiochemistryBioSinoDojindo LaboratoriesKAINOS LaboratoriesDAAN Gene

The report on the Global biochemical diagnostic reagent Market offers data of previous years along with in-depth analysis from 2021 to 2027 on the basis of revenue (USD Billion). Besides, the report offers a comprehensive analysis of the factors driving and restraining the growth of the market coupled with the impact they have on the demand over the forecast period.

biochemical diagnostic reagent Market By Types

Liquid Double ReagentDry Powder Double Reagent

biochemical diagnostic reagent Market By Applications

HospitalClinicLaboratory

Check Discount For This Report: https://marketstrides.com/check-discount/biochemical diagnostic reagent

This report forecasts revenue growth at the global, regional, and local levels and provides an analysis of the most recent industry trends from 2021 to 2027 in each of the segments and sub-segments. In addition, the report highlights the impact of COVID-19 on the Global biochemical diagnostic reagent Market and how the market is undertaking measures to reduce the losses. Some of the major geographies included in the market are given below:

Key Questions Answered in the Report:

Full Report:https://marketstrides.com/report/biochemical diagnostic reagent

RocheBeijing Strong BiotechnologiesRandoxSiemens HealthineersFosunPharmaBeckman CoulterSysmexBeijing Leadman BiochemistryBioSinoDojindo LaboratoriesKAINOS LaboratoriesDAAN Gene

And More

Contact UsCompany Name: Market StridesContact Person: Nikolai EggerCall: +1 856 677 8909 (US)Email: sales@marketstrides.com

Originally posted here:
biochemical diagnostic reagent Market Report Examines Business Opportunity and Worldwide Scope by Forecast 2021 to 2026 The Courier - The Courier

Turning Yeast Cells Into Labs For Studying Drivers of Gene Regulation – NC State News

Posted on July 6, 2021 by Danzig

Researchers have developed a more efficient platform for studying proteins that play a key role in regulating gene expression. The approach uses engineered yeast cells to produce enzyme and histone proteins, conduct biochemical assays internally, and then display the results.

Biomedical and biotech researchers are interested in the mechanisms that allow histones to regulate gene activity, says Alison Waldman, first author of a paper on the work and a Ph.D. student at North Carolina State University. But the conventional tools for histone research are unwieldy and slow. We wanted to develop something faster and less expensive and we did.

In complex organisms, chromosomes are largely made up of DNA and a group of proteins called histones. These histones are important for packing the DNA into chromosomes properly, but also play a role in regulating gene expression. In other words, they help determine when and how specific genes are turned on or off.

One of the features that makes histones challenging to study is that they often have chemical modifications that, alone or in combination, alter the role the histone plays in gene expression.

Histones essentially serve as docking sites for other proteins that influence gene expression, and the chemical modifications we see on histones play a role in determining which proteins have access to a given gene, says Balaji Rao, co-corresponding author of the paper and a professor of chemical and biomolecular engineering at NCState.

And to make matters more complicated, this is a dynamic process. A histone may have no modifications, it may retain a modification for the entire life of the cell, or modifications may be added and removed repeatedly. There is, in short, a lot going on. And enzymes are the catalysts responsible for all of those changes. Basically, enzymes are the mechanism for attaching or removing histone modifications.

So if you really want to understand whats going on with histones, you have to understand the chemical modifications. But if you want to understand the chemical modifications, you need to understand which enzymes are present and what they are doing.

Conventional methods for understanding how enzymes modify a histone involve using one of two techniques. First, you could use chemical synthesis to create enzymes and histone proteins, then conduct an assay in a test tube to see what happens. Second, you could genetically engineer one bacteria to produce an enzyme and engineer other bacteria to produce histone proteins, then harvest the relevant proteins, purify them, then conduct an assay to see what happens.

Our technique uses a genetically modified yeast cell to produce both the enzyme and the histone, Waldman says. The chemical modification takes place within the cell, and the resulting modified histone is sent to and displayed on the surface of the cell.

In other words, the yeast cell makes the relevant proteins, does the assay for you, and then displays the result on top, says Albert Keung, co-corresponding author of the work and an assistant professor of chemical and biomolecular engineering at NCState.

The modified yeast platform is significantly faster than conventional techniques. For example, examining a single enzyme/histone pairing would take a couple days, instead of a week.

But its easier to scale up than existing techniques, so you would save substantially more time if you were looking at a lot of proteins, Keung says.

In addition, there are some proteins that cant be made using chemical synthesis, or that cant be purified, Rao says. Our technique doesnt require chemical synthesis or purification, which means we can look at proteins that were difficult or impossible to assay in the past.

The researchers demonstrated the utility of the technique by having engineered yeast cells produce two types of histones and a well-studied enzyme called p300, which adds a specific acetyl group modification to histones.

Weve shown that our technique works, Waldman says. The next step is to begin expanding the modifications were looking at and scaling up the process.

The paper, Mapping the Residue Specificities of Epigenome Enzymes by Yeast Surface Display, is published in the journal Cell Chemical Biology. The work was done with support from the National Science Foundation, under grant 1830910; and the National Institutes of Health, under grant R21EB023377.

-shipman-

Note to Editors: The study abstract follows.

Mapping the Residue Specificities of Epigenome Enzymes by Yeast Surface Display

Authors: Alison C. Waldman, Balaji M. Rao and Albert J. Keung, North Carolina State University

Published: June 28, Cell Chemical Biology

DOI: 10.1016/j.chembiol.2021.05.022

Abstract: Histone proteins are decorated with a combinatorially and numerically diverse set of biochemical modifications. Here we describe a versatile and scalable platform which enables efficient characterization of histone modifications without the need for recombinant protein production. As proof-of-concept, we first used this platform to rapidly profile the histone H3 and H4 residue writing specificities of the human histone acetyltransferase, p300. Subsequently, a large panel of commercially available antiacetylation antibodies for their specificities, identifying many suitable and unsuitable reagents. Further, enabled efficient mapping of the large binary crosstalk space between acetylated residues on histones H3 and H4 and uncovered previously unreported residue interdependencies affecting p300 activity. These results show that using yeast surface display to study histone modifications is a useful tool that can advance our understanding of chromatin biology by enabling efficient interrogation of the complexity of epigenome modifications.

More here:
Turning Yeast Cells Into Labs For Studying Drivers of Gene Regulation - NC State News

Massive Growth of Biochemical Reagents Market by 2027 | Roche Holding AG, Thermo Fisher Scientific Inc., Siemens Healthineers, Abbott Laboratories …

Posted on April 30, 2021 by Danzig

Get Sample Report Buy Complete Report

Biochemical Reagents Market research report is the new statistical data source added by A2Z Market Research.

Biochemical Reagents Market is growing at a High CAGR during the forecast period 2021-2027. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Biochemical Reagents Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=471425

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

Roche Holding AG, Thermo Fisher Scientific Inc., Siemens Healthineers, Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Merck and Co. Inc., Johnson and Johnson, Waters Corporation, BD.

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Biochemical Reagents market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Biochemical Reagents markets trajectory between forecast periods.

Global Biochemical Reagents Market Segmentation:

Market Segmentation by Type: Cell and Tissue Culture Reagents, Chromatography Reagents, Electrophoresis Reagents, Polymerase Chain Reaction (PCR) Reagent Kits, Other.

Market Segmentation by Application: Hospitals, Diagnostic Centers, Academics and Research, Pharma and Biotech Companies.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=471425

Regions Covered in the Global Biochemical Reagents Market Report 2021: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The cost analysis of the Global Biochemical Reagents Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Biochemical Reagents market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Biochemical Reagents market.

Table of Contents

Global Biochemical Reagents Market Research Report 2021

Chapter 1 Biochemical Reagents Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Biochemical Reagents Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=471425

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

https://neighborwebsj.com/

Considerations for Tracer Selection to Assess Biochemical Recurrence in Prostate Cancer – Cancer Network

Posted on April 30, 2021 by Danzig

Raoul S. Concepcion, MD, FACS: Dr Ghesani, educate us. You deal with this a lot, and you understand. You have a tracer, and then there are nuances to this based on half-life. Gallium has a particular half-life, and F-18 [fluorine-18] has a particular half-life. Obviously, choline has a particular half-life. How does that impact and how does that play out potentially, as these scans are made more available to the general practitioner, the community urologist and oncologist? What are the factors there that the practitioners need to know that are the nuanced differences between thosetracers?

Munir Ghesani, MD: I would like to make 2 more points that I just started thinking about as Brian and Judd mentioned those items. I would like to add on those as well. As Brian referenced, there are data that show theres less than 20% sensitivity for combination of bone scans and CT [computerized tomography] scans in the setting of biochemical recurrence. Theres even a bigger problem, which is that in the small minority of the patients where the scans pick up the disease, its misleading because it does not fully clarify the extent of disease. Therefore, if you superficially look at it, you will see about 20% or less benefit. But in fact, even a subgroup of those patients does not benefit because their disease has not been properly delineated. They may have disease that was picked up only in part by the CT and bone scans, and you may end up targeting your treatment and not recognizing that there may be disease outside what the CT and bone scan did not pick up.

For that reason, it will be important to work with the CMS [Centers for Medicare & Medicaid Services] and other providers, and we are aggressively working in various societies by collaborating with one another to make these points clear. Hopefully, soon, these requirements for bone scans and CT scans will not be there. The second point I wanted to mention was in that polling question, the item about other, and this brings back to your question about all different options. There is also fluorine-18 FDG [fluorodeoxyglucose], which is the most used agent for most other cancers. It has been shown that for most cancers in the prostate it does not work, but with a very high Gleason score, they have very high level of glucose metabolism. Therefore, in a select and small subgroup of patients who have known to have a very high Gleason score, when they recur, one should also consider the possibility of FDG PET [positron emission tomography scan] or CT because in that subgroup, it is going to be very powerful.

Regarding your question about how we should choose. At the current level, the fluorine-18 half-life of 2 hours is readily available all around. It will be easy for the sides. Even after bone scan and CT scans have been negative, you have gone through the peer-to-peer and have an approval of fluciclovine, which would be the most used agent across the country at this time. For those sites that have the availability of gallium PSMA [prostate-specific membrane antigen] through the cross-referencing IND [investigational new drug] or clinical trials, but those would be mostly major academic centers. They can consider using gallium or fluorine PSMA-based agents. For small sitesthe Mayo Clinic, for examplewhere the C-11 choline was first developed, they can with cyclotron availability produce in a large batch, and we know that sites like the Mayo Clinic are doing a large number of carbon-11 PSMA scans.

Raoul S. Concepcion, MD, FACS: That is a limitation, isnt it? The half-life of the C-11 is so short that they cant

Munir Ghesani, MD: Its 20 minutes.

Raoul S. Concepcion, MD, FACS: You cant ship it a distance. To any of you, we know that fluciclovine Axumin is approved. It is approved in patients who have been treated for prostate cancer and have a rising PSA [prostate-specific antigen]. Correct me if Im wrong, but doesnt that include patients on active surveillance whose PSA [is rising]? Can you make the argument that active surveillance is a treatment and if they have a rising PSA, you could get fluciclovine? Have any of you tried that?

Brian Helfand, MD, PhD: You can make that argument. I dont think its correct. Ive seen it done, and its not really the FDA indication. What they mean is that interventions with curative intent, or subsequent hormone therapy that the patient is progressing. However, active surveillance was not part of that initial approval indication. Having said that, in the world many things are done whether theres evidence or not evidence for that. Therefore, we dont generally monitor our active surveillance patients with that.

Raoul S. Concepcion, MD, FACS:Perfect.

Transcript edited for clarity.

More:
Considerations for Tracer Selection to Assess Biochemical Recurrence in Prostate Cancer - Cancer Network

IIT Madras researchers find new method to make AIDS drug more effective – Business Today

Posted on February 20, 2021 by Danzig

Researchers at the Indian Institute of Technology, Madras claim to have found a novel way to make HIV/AIDS drugs more effective. The findings of their study, published in Biochemistry, the peer-review Journal of the American Chemical Society, say that introducing electrostatic interaction sites on potential drug molecules can enhance the efficacy of the antiviral drug against the HIV virus. The research was led by Prof. Sanjib Senapati, Department of Biotechnology, IIT Madras, along with research scholars Mohammed Ahsan and Chinmai Pindi.

"Current inhibitors (molecules that bind with the enzyme, thereby making it unavailable to the virus for growth and maturation) that target HIV-1 protease (HIVPR, an essential enzyme that is used by the AIDS virus for growth and maturation), make use of the weak forces of attraction called 'van der Waal's forces' to attach themselves to the protease molecule. Given that these forces are weak, the efficacy of the drug is variable and the virus will soon become resistant to them," Prof. Senapati, says.

The Molecular Dynamics (MD) simulation studies conducted by IIT Madras researchers showed the presence of a strong and asymmetrical electric charge in the active site of the HIVPR. If a drug molecule can be designed with a complementary charge, so that it can bind tightly with this active site through electrostatic attraction, it can permanently deactivate/inhibit the enzyme, they felt.

"Current drugs lack this electrostatic complementarity. This must be investigated because it is well-known that electrostatic forces between molecules are much stronger than van der Waals forces," Prof. Senapati said.

The researchers propose that drug design strategies should embrace both electrostatics and van der Waals interactions to complement the HIVPR active site architecture. Further, the team believes that such compounds will be effective against both wild-type and resistant HIV variants. According to them, it is a paradigm-shifting idea and will offer a whole new approach to the development of drugs for HIV-AIDS.

Prof. Chandra Verma, who has a Ph.D. from Bioinformatics Institute, A*STAR, Singapore, and is not involved in this IIT Madras Research, predicts a bright future for HIV drug development, with such knowledge base.

AIDS is one of the most devastating diseases and is a major cause of death among youth in many parts of the world. Since its outbreak nearly four decades ago, tremendous efforts have been directed towards development of antiretroviral therapies that target different stages in the life cycle of the virus that causes this deadly disease.

Also read: India issues fresh Covid-19 guidelines for travellers from UK, Brazil, South Africa

Also read: BT Business Leaders of TN: Manufacturing, electronics, SaaS can make India $5 trillion economy, say experts

Here is the original post:
IIT Madras researchers find new method to make AIDS drug more effective - Business Today

Global Biochemical Methane Market 2020 Size Share Upcoming Trends Segmentation And Forecast To 2026 – The Courier

Posted on February 20, 2021 by Danzig

The report aims to provide a high-quality and concise overview of the globalBiochemical Methane market, taking into account demand trends, competitive intelligence and technological challenges and developments, and other important topics. The cleverly crafted market analysis helps market players to understand the most important developments affecting their business in the global Biochemical Methane industry. Readers can become conscious of the vital opportunities on the global market for Biochemical Methane including the important aspects that drive and arrest business growth. The research study also offers an in-depth geographical overview of the global market of Biochemical Methane and focuses on important concepts and solutions that market players should concentrate on for robust growth.

Get an Exclusive Sample Report @https://www.syndicatemarketresearch.com/sample/biochemical-methane-market

The research report is prepared using Industrial best practices and methodologies for primary and secondary research. The researchers take references from official websites, legal documents, and news articles including audited financial statements and perform face-to-face or telephone briefings for information and data collection with industry experts.

Key players covered:

Biochemical Methane Market By Type:

Biochemical Methane Market By Application:

Research Coverage:This is the first part of the research that covers market segmentation outlines, years studied, analysis targets, major global Biochemical Methane manufacturers, and product range.Overview:The report here puts the spotlight on market output, revenue, usage, and potential. It also brings market trends, drivers, restraints and macroscopic indicators to light.Profiles of companies:This section includes a broad examination of key players in the global Drug for Ulcerative Colitis market based on various factors such as the latest advances, market share and gross margins. This provides an analysis of SWOT, too.Regional Production:All the regions evaluated in the study are examined here based on key factors such as volume, sales, market share, import, and export.Regional demand:Each domestic market discussed here is evaluated based on the global markets share of sales and output.Product market penetration: comprises the study of costs, sales and industry overview by product type.

Also Read Our Top Most Reports:Industrial Safety Footwear,Remote Asset Management

For detailed information read ourProduct Specification

Read the original here:
Global Biochemical Methane Market 2020 Size Share Upcoming Trends Segmentation And Forecast To 2026 - The Courier

Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing…

Posted on February 20, 2021 by Danzig

NEW YORK, Feb. 18, 2021 /PRNewswire/ --Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced positive top-line data from an investigator-sponsored phase 2 proof-of-concept clinical trial of IMU-838 in primary sclerosing cholangitis (PSC). This single-arm, open-label, exploratory study was designed to investigate IMU-838's potential to improve various biochemical parameters in PSC patients and help determine whether any such activity warrants further investigation in randomized PSC trials. As previously announced, due to the COVID-19 pandemic, only 18 of the targeted 30 patients were enrolled in the study (intent-to-treat population, ITT), of whom only 11 patients completed the full IMU-838 treatment course and were evaluable over the 24-week treatment period (per-protocol population, PP).

The PP population experienced a statistically significant decrease in serum alkaline phosphatase (ALP) levels (p=0.041) after 24 weeks of treatment using 30 mg IMU-838 once daily, as compared to baseline. A consistent individual pattern of a stable decrease in ALP values was observed in the PP population between baseline and week 24, without any single patient showing an increase of more than 20% of ALP. As per the definition of the primary objective of the study, 27.3% of the patients in the PP population had a clinically relevant reduction of serum ALP higher than 25% at week 24, without an increase in liver biochemistry of more than 33%, as compared to baseline. Biochemical endpoints, such as changes in serum ALP, have been used in PSC trials performed by third parties.

Regarding the secondary objectives of the study, no changes in aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total, direct or indirect bilirubin were observed in the ITT or PP populations, as compared to baseline. In addition, despite the limited scope of the data, encouraging results were observed regarding symptoms of inflammatory bowel disease, a common comorbidity for PSC patients, and patient assessments of health-related quality of life. The study also found that IMU-838 is a safe and well-tolerated oral drug for PSC patients and treatment-emergent adverse events were rare and generally mild.

"I am very excited about the effects we have seen in this highly underserved patient population where there is only a small number of cases worldwide and where no pharmaceutical treatment option is currently available," noted Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. "We are also very pleased to see that IMU-838's safety and tolerability profile was confirmed in this patient group. The results from this small, open-label study suggest that IMU-838 merits further clinical testing in PSC. We are in discussions with investigators and leading clinical experts to further evaluate the data set and to explore potential next steps for this indication."

"Currently, no effective treatment options are available for PSC patients and the hepatology community is very keen to see new approaches and clinical programs for the investigation of promising new approaches. I am grateful that Mayo Clinic and Immunic are collaboratively exploring this underserved indication for which liver transplantation is often the only effective option," stated Keith Lindor, M.D., Professor of Medicine Emeritus and former President of the American Association for the Study of Liver Diseases. "Although we are mindful of the small size of this dataset, I do believe the results are noteworthy and merit further exploration. Notable in this small patient cohort is the absolute consistency with which these patients experienced decreases in serum alkaline phosphatase at the 24-week time point."

Study Background and Baseline Characteristics

The single-arm, open label, exploratory study was an investigator-sponsored trial led by Elizabeth Carey, M.D., Professor of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, who had received Investigator Investigational New Drug (IND) approval from the U.S. Food & Drug Administration (FDA) and had been granted Institutional Review Board (IRB) approval to conduct the study. The study was supported by a grant from the National Institutes of Health (NIH) and was conducted at two sites: Mayo Clinic, Phoenix, Arizona (Dr. Carey) and Mayo Clinic, Rochester, Minnesota (John E. Eaton, M.D.), both of which are tertiary referral centers for PSC patients.

The study, for which Immunic provided the study medication, planned to enroll 30 patients with PSC, aged 18 to 75 years, who received 30 mg of IMU-838 once daily for a period of 24 weeks. Enrollment for the study took place between July 2019 and September 2020, but almost all enrollment occurred in 2019 and early 2020. During the COVID-19 pandemic, recruitment for this study was hampered, as patients with PSC are at a high risk of COVID-19 infections and were advised to avoid travel and unnecessary social contacts such as those required to participate in a clinical trial. Together with the investigators, Immunic determined to readout data of the 18 patients who were enrolled prior to the COVID-19 pandemic. The ongoing COVID-19 pandemic also triggered the principal investigator's decision to terminate the study in late 2020, before the intended recruitment goal of 30 patients was reached.

A total of 18 patients started treatment of 30 mg IMU-838 once daily (intent-to-treat population, ITT, n=18). Of these 18 patients, 11 patients received the full 24-week treatment with IMU-838 (per-protocol population, PP, n=11). Due to the high number of discontinued patients during the COVID-19 pandemic and the fact that all discontinued patients in an ITT statistical analysis will be counted as treatment failures at week 24, this analysis focuses mainly on the 11-patient PP population.

Primary Objective

The primary objective of this study was to determine whether IMU-838 reduces serum ALP in adult patients diagnosed with PSC. The main analysis for the primary objective was whether patients could achieve a reduction of ALP at week 24 which is greater or equal to 25%, as compared to baseline, while the AST increase at week 24 is no more than 33%, as compared to baseline. This positive primary outcome was achieved by 3 of 11 patients in the PP population (27.3%, 95% CI: 6-61%). By virtue of inclusion criteria, patients at baseline had to have an elevated ALP value of at least 1.5 times upper limit of normal (ULN).

In addition, time from baseline was calculated as a continuous variable and treated as the primary predictor using a random intercept model which was adjusted for age at baseline and gender. For this longitudinal analysis of ALP from baseline to week 24 in the PP population, the ALP value statistically significantly (p=0.041) decreased by an average of 5.76 IU/L every 30 days (95% CI: -11.29, -0.23; statistical model). The time trend was not statistically significant in the ITT analysis (p=0.578) due to missing data following the high rate of treatment discontinuations during the COVID-19 pandemic.

Secondary Objectives

Secondary objectives were to investigate the liver biochemistry parameters, AST, ALT, and total/direct/indirect bilirubin, as well as the concentrations of proinflammatory cytokines, as compared to baseline. The longitudinal analysis of both AST and ALT as well as total, direct and indirect bilirubin values showed a stable pattern in the PP population with no statistically significant change over time and the confidence interval to include the no-change scenario (AST: average 30 day change 1.22 IU/L, 95% CI: -0.53, 2.97, p=0.170; ALT: average 30 day change 0.85 IU/L, 95% CI -1.46, 3.15, p=0.467, total bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.02, p=0.561, direct bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.01, p=0.861, indirect bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.01, p=0.556). Similar results were found in the ITT population. In addition, a decrease in the Ulcerative Colitis Clinical score was observed in evaluated patients, although the number of assessed patients was limited.

"This was a feasibility study to explore activity of IMU-838 in PSC patients based on biochemical parameters. IMU-838 was found to lead to a statistically significant reduction of serum ALP over time in the PP population, while no trend for increases in ALT, AST or bilirubin was observed," commented Andreas Muehler, M.D., Chief Medical Officer of Immunic. "Despite the challenges we faced due to COVID-19, which severely hindered the enrollment at the two Mayo Clinic sites and which led to an unusually high discontinuation rate and an early termination of the study, we have seen encouraging activity signals for IMU-838 in this patient population. Based on these promising data and, in particular, the improvement in biochemical liver parameters, we will continue to evaluate the potential of IMU-838 as a treatment option for PSC patients. It may also be worthwhile to optimize dose levels of IMU-838 in PSC patients in the future."

For more information on this clinical trial, please visit: http://www.clinicaltrials.gov, NCT03722576.

Conference Call and Webcast Information

As previously announced, Immunic's management team will host a public conference call and webcast today, February 18, 2021 at8:00 a.m. Eastern Timeto discuss the data from the main phase 2 analysis of the CALVID-1 trial of IMU-838 in hospitalized patients with moderate COVID-19, as well as data from the investigator-sponsored phase 2 clinical trial of IMU-838 in primary sclerosing cholangitis.

To participate in the conference call, dial 1-877-870-4263 (USA) or 1-412-317-0790 (International) and ask to be joined into the Immunic, Inc. call. A live, listen-only webcast of the conference call can be accessed at https://www.webcaster4.com/Webcast/Page/2301/39950or on the "Events and Presentations" section of Immunic's website at ir.imux.com/events-and-presentations.

An archived replay of conference call and webcast will be available approximately one hour after the completion for one year on Immunic's website at: ir.imux.com.

About Primary Sclerosing Cholangitis (PSC) PSC is a rare liver disease with a prevalence of approximately 4.15 per 100,000 in the United States, in which the bile ducts in the liver become inflamed, narrow and prevent bile from flowing properly. The exact cause and disease mechanism of PSC are still unknown, but an autoimmune mechanism may play a role. There is an association with inflammatory bowel diseases, most often with ulcerative colitis and less commonly with Crohn's disease. PSC is a progressive disease and, other than liver transplantation, there are currently no approved therapies that have been shown to improve survival in patients with PSC. The estimated time from diagnosis of PSC to death or liver transplant has been shown to be less than 15 years.

About IMU-838IMU-838 is an orally available, next-generation selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase (DHODH). IMU-838 acts on activated T and B cells while leaving other immune cells largely unaffected and allows the immune system to stay functioning, e.g. in fighting infections. In previous trials, IMU-838 did not show an increased rate of infections compared to placebo. In addition, DHODH inhibitors, such as IMU-838, are known to possess a host-based antiviral effect, which is independent with respect to specific virus proteins and their structure. Therefore, DHODH inhibition may be broadly applicable against multiple viruses. IMU-838 was successfully tested in two phase 1 clinical trials in 2017 and is currently being tested in a phase 2 trial in patients with ulcerative colitis. In the third quarter of 2020, the company reported positive results from its phase 2 EMPhASIS trial of IMU-838 in relapsing-remitting multiple sclerosis, achieving both primary and key secondary endpoints with high statistical significance. In the first quarter of 2021, Immunic announced that IMU-838 has shown evidence of clinical activity in its phase 2 CALVID-1 trial in hospitalized patients with moderate COVID-19. Also, in the first quarter of 2021, the company reported positive top-line data from an investigator-sponsored phase 2 proof-of-concept clinical trial of IMU-838 in primary sclerosing cholangitis which was conducted in collaboration with Mayo Clinic. To date, IMU-838 has been tested in more than 800 individuals and has shown an attractive pharmacokinetic, safety and tolerability profile. IMU-838 is not yet licensed or approved in any country.

About Immunic, Inc.Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company witha pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Immunic is developing three small molecule products: its lead development program,IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORt; and IMU-856 targets the restoration of the intestinal barrier function. For further information, please visit: http://www.imux.com.

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's three development programs and the targeted diseases; the potential for IMU-838 to safely and effectively target diseases; the proof-of-concept study of IMU-838 for the treatment of patients with primary sclerosing cholangitis; the timing of current and future clinical trials; the potential for IMU-838 as a treatment for primary sclerosing cholangitis that may be supported by the investigator-sponsored phase 2 proof-of-concept trial data, and any clinical trials, collaborations and approvals relating to such potential treatment; the nature, strategyand focus of the company; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020, the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the SEC on November 6, 2020, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information

Immunic, Inc. Jessica BreuHead of Investor Relations and Communications+49 89 2080 477 09[emailprotected]

US IR ContactRx Communications GroupPaula Schwartz+1 917 322 2216[emailprotected]

US Media ContactKOGS CommunicationEdna Kaplan+1 781 639 1910[emailprotected]

SOURCE Immunic, Inc.

http://www.immunic-therapeutics.com

View original post here:
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing...

Electrolyte and Biochemistry Analyzers Market is slated to grow rapidly in the forthcoming years with Top Leading Players y, z etc., etc The Bisouv…

Posted on February 20, 2021 by Danzig

This report also covers the impact of COVID-19 on the global market. The pandemic caused by Coronavirus (COVID-19) has affected every aspect of life globally, including the business sector. This has brought along several changes in market conditions.

New Research Study on Electrolyte and Biochemistry Analyzers Market Growth of 2020-2026: The Global Electrolyte and Biochemistry Analyzers Market report provides readers with a comprehensive resource that contains a detailed analysis of the market in the industry that can be accessed and refurbished to gain additional information and better understanding of the industry. The research report includes statistics and data that answer important business questions like how the Global Electrolyte and Biochemistry Analyzers Market will perform in the existing market scenario. It also provides valuable information regarding the latest trends in the industry. Furthermore, the research report presents the potential industry supply, market demand, market value, market competition, key market players and the industry estimate from 2020-2026.

To get SAMPLE of the report, please click:https://www.reportsmonitor.com/request_sample/1192207

TheMajorPlayers Covered in this Report: x, y, z etc. & More.

Market segment by TypeElectrolyte AnalyzersBiochemistry Analyzers

Market segment by ApplicationHospitalClinicLabsOthers

Global Electrolyte and Biochemistry Analyzers Market: Regional AnalysisThe report offers in-depth assessment of the growth and other aspects of the Electrolyte and Biochemistry Analyzers market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2027. These analyses will help the reader to understand the potential worth of investment in a particular region.

Global Electrolyte and Biochemistry Analyzers Market: Competitive LandscapeThis section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.

The study also provides an overview of the Global Electrolyte and Biochemistry Analyzers Market, considering the key geographies and the segmentation. The report also studies the distribution channels and the latest technological advancements in the market. The report also studies the prevailing challenges that the industry is facing currently. This study is intended to provide the experts and professionals with a competitive benchmarking of the Global Electrolyte and Biochemistry Analyzers Market. The study provides the up-to-date information on the market share, key strategies of the leading players, profit margins, and capabilities.

Some of the key geographies mentioned in this report include:

To get this report at a profitable rate @https://www.reportsmonitor.com/check_discount/1192207

Major factors covered in the report:

The analysis objectives of the report are:

View this report with a detailed description and TOC @https://www.reportsmonitor.com/report/1192207/Electrolyte-and-Biochemistry-Analyzers-Market

Any special requirements about this report, please let us know and we can provide custom report.

Contact UsJay MatthewsDirect: +1 513 549 5911 (U.S.)+44 203 318 2846 (U.K.)Email: [emailprotected]

Go here to read the rest:
Electrolyte and Biochemistry Analyzers Market is slated to grow rapidly in the forthcoming years with Top Leading Players y, z etc., etc The Bisouv...

Trending Report on Biochemical Diagnostic Reagent Market Business Insights and Development Analysis from 2020-2027 | Top Players Siemens…

Posted on February 20, 2021 by Danzig

Recent Industry trends & research observe on Global Biochemical Diagnostic Reagent Market 2020 & Forecast 2027 highlights various agency elements like types, end-users, programs. The competitive landscape view in Biochemical Diagnostic Reagent Industry, mergers & acquisitions, research, new technologies & upcoming Biochemical Diagnostic Reagent companies are pro-Report Sheet. The market size, modern employer trends, government policies, & investment opportunities in the Biochemical Diagnostic Reagent Industry are covered.

Continue

Get Sample Report + All Graphs & Charts @ https://www.crystalmarketresearch.com/report-sample/HC0114730

The points which can be discussed within the report are the predominant Biochemical Diagnostic Reagent industry players that might be involved inside the Biochemical Diagnostic Reagent market, the entire proReport Sheet of the companies is mentioned.

The production, sales, future strategies, and the technological traits that theyre making are also included in the Biochemical Diagnostic Reagent industry Report Sheet.

The increased factors of the Biochemical Diagnostic Reagent market are mentioned in detail wherein the different give up customers of the market are explained in detail.

The application areas of the Biochemical Diagnostic Reagent market are also discussed accordingly giving a broad concept approximately the industry to the clients.

The Biochemical Diagnostic Reagent industry report incorporates the SWOT evaluation of the industry. Finally, the Report Sheet contains the conclusion component where the opinions of the commercial specialists are included.

For Early Buyers | Get Up to 10% Discount @ https://www.crystalmarketresearch.com/check-discount/HC0114730

Click Here to Enquire More @ https://www.crystalmarketresearch.com/send-an-enquiry/HC0114730

Contacts Us:

Crystal Market Research

http://www.crystalmarketresearch.com

Sherry | APAC Marketing Division: Level 23-1, Premier Suite, Mont Kiara, 50480 Kuala Lumpur, Malaysia

E-mail: sales@crystalmarketresearch.com | Ph: +1-888-213-4282

See the original post here:
Trending Report on Biochemical Diagnostic Reagent Market Business Insights and Development Analysis from 2020-2027 | Top Players Siemens...

Biochemical Clues Reveal How Some Corals Resist Bleaching From Climate Change That Is Killing Coral Reefs – SciTechDaily

Posted on February 15, 2021 by Danzig

A comparison of resistant (left) and bleached (right) corals. Credit: Courtesy of Ty Roach (HIMB)

Climate change is bleaching and killing corals, but researchers from Michigan State and the University of Hawaii are investigating how some can stand up to a warming world.

Coral reefs are beautiful and diverse ecosystems that power the economies of many coastal communities. Theyre also facing threats that are driving their decline, including the planets warming waters.

This threat hit extreme levels in 2015, when high temperatures were turning corals white around the globe. Kaneohe Bay in Hawaii was hit hard; nearly half of its corals bleached.

Hidden in the aftermath of this extreme event, however, were biochemical clues as to why some corals bleached while others were resistant, information that could help reefs better weather warming waters in the future. These clues have now been uncovered by researchers at Michigan State University and the University of Hawaii at Manoa.

It was kind of horrifying, said coral biologist Crawford Drury, who witnessed 2015s bleaching event from Florida before joining UH Manoas Hawaii Institute for Marine Biology, or HIMB. Its disheartening to watch, but I try to think of it as an opportunity.

How this disturbing event became an opportunity is now clear thanks to a February 8, 2021, report in Nature Ecology & Evolution that showcases HIMBs stewardship and MSUs biochemical expertise.

Coral samples were analyzed by mass spectrometry to investigate biochemical differences. Credit: Courtesy of Ty Roach (HIMB)

The researchers discovered chemical signatures in the corals biology, or biomarkers, that are present in organisms that were most resistant to the bleaching. This previously hidden insight could help researchers and conservationists better restore and protect reefs around the world.

Usually, we think of biomarkers as signatures of disease, but this could be a signature of health, said MSUs Robert Quinn, an assistant professor in the Department of Biochemistry and Molecular Biology. This could help us restore reefs with the most resistant stock.

Corals are symbiotic communities where coral animal cells build homes for algae that provide them energy and create their colors. When corals bleach, however, the algae are lost and leave behind skeletons that are susceptible to disease and death.

This symbiosis also plays a role in a corals resistance and resilience to bleaching, which HIMB was in a unique position to investigate literally. The institute sits right next to the reef, enabling experiments in real time.

The reef is about 100 feet away, Drury said. I could be there in 30 seconds.

During the 2015 bleaching event, researchers in the Gates Coral Lab at HIMB had tagged individual corals to keep tabs on them. Because most of the corals recovered, the team could follow them over time.

We think about it as a biological library, said Drury, the principal investigator with the Gates Coral Lab. It was set up by researchers in our lab who knew it would be very valuable.

A view of coral reefs near Hawaiis shores, where bleaching was prevalent in 2015. Credit: Photo courtesy of Ty Roach (HIMB)

Following the bleaching, the team compared and contrasted coral samples in the wild, noting how the organisms responded and recovered, making some surprising observations along the way. For example, neighboring corals could behave completely differently in response to high temperatures. One coral could bleach completely while its neighbor maintained a healthy golden hue.

To understand why, Drury and HIMB postdoctoral researcher Ty Roach, the lead author of the study, sent samples to Quinn at MSU. Here, Quinn and his team could thoroughly analyze the biochemicals of corals collected from this biological library using a method called metabolomics.

Im known more for my medical work, said Quinn, who studies the biochemistry of health and disease in humans. But Ive always loved ocean science. My background is in marine microbiology.

If the coral samples are the books in the library, Quinns lab used sophisticated equipment to reveal the biochemical language within. In particular, his team used tools known as mass spectrometers to understand what set resistant corals apart from susceptible ones.

The corals are completely different in their chemistry, but you cant tell until you run the mass spec, Quinn said. These mass specs are some of the most advanced technology on the planet.

Quinns team found that corals that were resistant to bleaching and those that were susceptible hosted two different communities of algae. The distinguishing feature between these algal populations was found in their cells, in compounds known as lipids.

The researchers metabolomic analysis detected two different lipid formulations. Bleaching-resistant corals featured algae that have what are known as saturated lipids. Susceptible corals had more unsaturated lipids.

This is not unlike the difference between oil and margarine, the latter having more saturated fat, making it solid at room temperature, Quinn said.

This discovery poses all sorts of new questions for researchers: How do the corals get these different algae? Is this difference unique to Hawaiian corals or can it be found elsewhere? How can researchers promote the growth and proliferation of resilient corals in a warming world?

Mass specs are such incredible machines and reveal intricate details of the chemistry involved. The biology is really the hard part. Quinn said. Were working on new grants. There are so many avenues to explore.

This initial project was funded by the Paul G. Allen Family Foundation.

This collaboration has been a great opportunity to ask and answer questions, Drury said. Hopefully, were just getting started.

In the meantime, having this chemical information is promising for coral conservation. When conservationists reseed corals to help restore reefs, they can potentially select more resilient specimens.

We can use natural resilience to better understand, support, and manage coral reefs under climate change, Drury said.

Conservation biology has some of the more successful stories in modern scientific history, Quinn said, pointing to the resurgence of elk in Virginia and bald eagles in Michigan. Someday, maybe we can add corals to that list.

Reference: Metabolomic signatures of coral bleaching history by Ty N. F. Roach, Jenna Dilworth, Christian Martin H., A. Daniel Jones, Robert A. Quinn and Crawford Drury, 8 February 2021, Nature Ecology and Evolution.DOI: 10.1038/s41559-020-01388-7

Funding: Paul G. Allen Family Foundation

Read this article:
Biochemical Clues Reveal How Some Corals Resist Bleaching From Climate Change That Is Killing Coral Reefs - SciTechDaily

Dr. Joseph Angel de Soto named the Editor & Chief of the Journal of Advanced Biochemistry and Research – Martinsburg Journal

Posted on February 15, 2021 by Danzig

GERRARDSTOWN Dr. Joseph Angel de Soto, of Gerrardstown, has been named editor and chief of "The Journal of Advanced Biochemistry and Research."

He is currently the editor of "Virology Research & Reports." Dr. Soto received his doctorate in medicine and a Ph.D. in pharmacology from Howard University. His dissertation was titled, The Treatment of Breast Cancer with Chemo-hormonal Therapy. He also completed doctoral studies in national security and intelligence.

His clinical medical training was at Howard University Hospital and Washington Hospital Center. He then completed his fellowship at the National Institutes of Health in pharmacogenomics and translational oncology, where he was the fellow of the year.

He has published over 150 articles and papers. As a professor, he has been faculty of the year seven times. De Soto also received the ASCO Cancer Researcher of the Year award. According to the publishers of "The Journal of Advanced Biochemistry and Research," he is considered one of the top physician-scientist and pharmacogeneticists in the world.

For more information, visit the Journal of Advanced Biochemistry and Research website: https://snipub.com/journal-of-advanced-biochemistry/editorial-board-journal-of-advanced-biochemistry/.

Excerpt from:
Dr. Joseph Angel de Soto named the Editor & Chief of the Journal of Advanced Biochemistry and Research - Martinsburg Journal

Biochemistry professor Tansey discovers protein that could melt tumors – The Vanderbilt Hustler

Posted on February 15, 2021 by Danzig

The discovery of MYC-HCF1 interactions may lead to a future tumor-shrinking treatment.

Vanderbilt University Medical Center (VUMC), pictured above, manages more than 2 million patients each year and is one of the largest academic medical centers in the Southeast, according to its website. (Hustler Multimedia/Truman McDaniel)

On Jan. 8, a study published in the journal eLIFE by Vanderbilt professor of biochemistry and cell and developmental biology, Dr. William Tansey, detailed the discovery of a genetic mutation that can be applied to shrink tumors quite quickly.

The protein, called MYC, is used by animals and humans alike for cell division and cell growth, which also allows tumor cells to rapidly expand. Tumors typically form when cells no longer have control of their growth, and MYC often enables cells to grow out of control, creating tumors. When Tansey and colleagues discovered a particular mutation that blocks the interaction between MYC and another protein, Host Cell Factor-1 (HCF1), tumors rapidly shrunk.

The next step, according to Tansey, is to identify certain molecules that are able to bind to HCF1 to prevent it from interacting with MYC.

Now that we know what we have to go after, the question is if we can do this beneficially and safely, Tansey said.

If molecules that bind to HCF1 are able to be identified, clinical trials could begin within the next decade for a potential tumor-melting clinical drug in the distant future, according to Tansey. However, the process is often long, and it may take years before this discovery is manifested into a drug, per Tansey.

If you had a molecule that was able to bind to HCF1 and prevent it from being touched by MYC, then that could form the basis of a future anti-cancer drug, Tansey said.

This discovery is the second time that a cancer-treating drug was discovered at Vanderbilt. In 2015, Vanderbilt professor of biochemistry, pharmacology and chemistry, Stephen Fesik, alongside Tansey, discovered a protein named WDR5 that similarly halts interactions with MYC. WDR5 is expected to be in clinical trials shortly, and is currently supported by the National Cancer Institutes Experimental Therapeutics Program, according to Tansey.

We are looking for something that will treat pre-existing tumors, and it seems as if this discovery could lead down that path, Tansey said.

Alumnae Key to Nationwide Work on COVID-19 Vaccine – Kettering University News

Posted on February 15, 2021 by Danzig

Four alumnae specializing in documentation, chemical testing, quality control and software analysis have joined the fight against COVID-19.

The women Aubrie (Hoffman) Eaton, Mia (Jonascu) Hillaker, Debra (Pratt) Piper and Katie (Esch) VandeBerg all work at Par Pharmaceutical in Rochester, Mich., and apply their skills learned while they were students at Kettering University to the production of various sterile injectable products, including a potential vaccine for COVID-19.

Par Sterile began production on NVX-CoV2373, a protein-based COVID-19 vaccine candidate from Novavax, Inc. in September 2020. In December, Novavax announced the initiation of Phase 3 clinical trials in the United States and Mexico, and in January announced highly encouraging efficacy results from trials taking place in the United Kingdom and South Africa.

Its very humbling, said Quality Control Chemist VandeBerg (17, Chemistry). Its nice to know that were part of the effort attempting to make a difference in the fight against COVID and how its being treated.

Its not the front line, but its close to it in light of the fact that we are involved with the production of a potential COVID-19 vaccine, she added. Its very cool to be working on something that may have a big impact in our history.

Science, Safety and Steps to Save Lives

VandeBerg, who has been with the company since October 2017, conducts tests on raw materials before they head to production.

We put a lot of good time and effort into making sure its done the right way every time, VandeBerg said.

Materials then head to Senior Scientist Eaton (14, Biochemistry), who is responsible for chemical testing at various stages of production and completion to ensure the product meets safety standards and performs as it should.

It has been interesting. Its been moving very quickly, Eaton said. The assumption is fast means reckless, and that upsets me. There is a high level of integrity in the scientific field with defined processes and procedures. The FDA doesnt just approve things.

Eaton has been at Par Pharmaceutical since September 2020. She said this work has given her a sense of purpose.

We are by no means on the front lines, but its important to recognize that we, scientists, are very focused on working on solutions to protect those heroes, Eaton said.

Neither Eatons nor VandeBergs jobs could be done without the work of Scientist Debra Piper (13, Biochemistry). She supports the laboratory by implementing the software and analysis systems used with the testing equipment to ensure they are used appropriately and efficiently.

Piper started working at Par as part of Kettering Co-op as a student. There until 2016, she worked elsewhere for four years but returned to Par in the spring of 2020.

Its a great feeling to know your job may actually have an impact on people, and what youre doing is going toward a common cause we all want to support, Piper said. It makes you respect your job more and enjoy your job more.

Documenting Success

However, these jobs cant be done without documentation, and thats where Hillaker (18, Applied Biology) comes in.

Hillaker, who is a Quality Document Associate for a little more than a year, ensures that documents needed for the process are correct so that all standards are met. Some of the documents include labels, testing forms and batch forms, which in the simplest terms, are similar to recipe cards for products.

It feels a little bit surreal, just because I go to work every day and think, Oh my goodness, my signature is going to be on some of these very crucial documents, she said.

Like her co-workers, Hillaker recognized the potential impact her job has on society.

The whole experience overall has been crazy, but wonderful, she said. The hours have been crazy, the workload has been crazy, but at the same time, it could help the greater good in a way that I wasnt expecting.

Piper has been able to do much of her work remotely, while Hillaker, Eaton and VandeBerg have been on site. Schedules were shifted to reduce the number of people in the facility at any one time to meet COVID-19 guidelines.

Kettering Mindset and Co-op Experience Give Valuable Advantage

The women said their time at Kettering University not only connects them, but has armed them with the skills and mindset to be successful in their jobs.

Ketterings slogan was Think Differently, Eaton said. I have found that I ask different sorts of questions because my mind thinks of several possibilities instead of the direct route. I have noticed when I ask questions, people say, Ive never thought about that. Its coming at things from different angles.

VandeBerg, Hillaker and Piper cited their Kettering Co-op experiences as great preparation for life after graduation. Piper said being able to enter the industry at a younger age than your counterparts from other colleges is a valuable advantage.

You can go to school and work at the same time and apply what youre learning while youre working, she said. It really teaches you how to excel in the workforce.

Hillaker said she knew it would be a good fit for her current job because of how much she enjoyed the elements of her Co-op experience as a scribe for the Hurley Medical Center.

I was kind of surprised in the ways that Kettering prepared me, she said. I was more prepared for the medical field, but through my Co-ops and research, I found that I liked the more technical side of it and computer science part. I really enjoyed working with the data and data models and attention to detail that you get with scribing.

Eaton and Piper said they appreciated the smaller classes, too.

A lot of these upper-level classes are very, very difficult, and once you get [to upper level] chemistry, class sizes were six to nine people, Eaton said. You dont have that in other college experiences.

She said the small classes allowed her to work with the entire class to study and prepare, and made her feel as if the professor was part of her team.

Piper echoed Eatons sentiments, noting there were four or five people from her discipline in her graduating class.

I think one of the things I enjoyed the most was when the four or five of us got together to hang out, work on school work and teach each other the lessons, Piper said. We all wanted to succeed together. There wasnt competition for who was going to be the best; we all wanted to be successful together and that was something I was able to do at Kettering. I think at larger schools youre not able to get that.

Read more from the original source:
Alumnae Key to Nationwide Work on COVID-19 Vaccine - Kettering University News

Non-Lethal Biochemical Weapons Market hits USD2.32 Bn by 2028 with Taser International Manufacturing Company, Combined Systems, The Safariland Group,…

Posted on February 15, 2021 by Danzig

The Non-Lethal Biochemical Weapons Market is expected to exhibit a CAGR of +8% to reach US$2.32 bn by the end of 2028.

Non-Lethal Chemical Weapons. The US military is currently engaged in several research efforts to develop non-lethal chemical and biological weapons. These weapons can be placed into two main categories: incapacitants and anti-material agents.

Bacillus anthracis bacteria, which causes anthrax, is one of the most deadly agents to be used as a biological weapon. It is classified by the US Centres for Disease Control and Prevention (CDC) as a Category A agent, posing a significant risk to national security.

The use of biological weapons is prohibited under customary international humanitarian law, as well as a variety of international treaties. The use of biological agents in armed conflict is a war crime.

Request for a sample report here @ https://www.reportconsultant.com/request_sample.php?id=80748

Major Key Players of the Market:

Taser International Manufacturing Company, Combined Systems Inc., The Safariland Group, Condor Non-lethal Technologies, BAE Systems, PLC, Herstal SA, Armament Systems & Procedures Inc, Raytheon Company, Lamperd Less Lethal Inc., Mission Less Lethal Technologies, Pepperball Technologies Inc., Lrad Corporation, Amtec Less Lethal Systems Inc.

Non-Lethal Biochemical Weapons Market Study guarantees you to remain/stay advised higher than your competition. With Structured tables and figures examining the Non-Lethal Biochemical Weapons, the research document provides you a leading product, submarkets, revenue size and forecast to 2028. Comparatively is also classifies emerging as well as leaders in the industry.

This study also covers company profiling, specifications and product picture, sales, market share and contact information of various regional, international and local vendors of Global Non-Lethal Biochemical Weapons Market. The market opposition is frequently developing greater with the rise in scientific innovation and M&A activities in the industry. Additionally, many local and regional vendors are offering specific application products for varied end-users. The new merchant applicants in the market are finding it hard to compete with the international vendors based on reliability, quality and modernism in technology.

Get upto 40% Discount available on this Report @ https://www.reportconsultant.com/ask_for_discount.php?id=80748

What to Expect from this Report on Non-Lethal Biochemical Weapons Market?

It provides a knowledge regarding Porters Five Forces including substitutes, potential entrants, buyers, industry competitors, and suppliers with genuine information for understanding the global Non-Lethal Biochemical Weapons market. Furthermore, it offers detailed data of vendors including the profile, specifications of product, sales, applications, annual performance in the industry, investments, acquisitions and mergers, market size, revenue, market share, and more.

Conclusions of the Global Non-Lethal Biochemical Weapons Market Professional Survey Report 2021 comprises:- Methodology, Analyst Introduction and Statistics Supply. In the end, the analysis comprises Non-Lethal Biochemical Weapons SWOT analysis, investment partialness investigation, investment include research and development tendency investigation.

About Us:

Report Consultant A worldwide pacesetter in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly by taking calculative risks leading to lucrative business in the ever-changing market. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies.

Our research reports will give you the most realistic and incomparable experience of revolutionary market solutions. We have effectively steered business all over the world through our market research reports with our predictive nature and are exceptionally positioned to lead digital transformations. Thus, we craft greater value for clients by presenting progressive opportunities in the global futuristic market.

Riaana Singh

(Report Consultant)

sales@reportconsultant.com

http://www.reportconsultant.com

See more here:
Non-Lethal Biochemical Weapons Market hits USD2.32 Bn by 2028 with Taser International Manufacturing Company, Combined Systems, The Safariland Group,...

North Carolina State University: Biochemical Sensor Researcher Makes MIT Technology Review’s List Of Top Young Innovators – Patch.com

Posted on July 6, 2021 by Danzig

Amay J. Bandodkar, an assistant professor of electrical and computer engineering at North Carolina State University, has been named one of MIT Technology Review's "Innovators Under 35" for his work on developing wearable biochemical sensors.

"I am very excited that Tech Review is recognizing our work to move health technology into the future," says Bandodkar. "I owe it to my amazing team members and mentors."

The annual list, which Tech Review has issued since 1999, was created to highlight exceptionally talented young innovators from around the world in a variety of fields. Previous winners include Mark Zuckerberg, Larry Page, Sergey Brin and Vivian Chu.

Bandodkar works at the interface of electronics, materials science, and biology to create next-generation wearable sensors with biomedical applications such as disease monitoring.

"My ultimate goal would be to develop technology that allows us to assess a person's health status by merely scanning a reader just like the tricorder from Star Trek," Bandodkar says.

Bandodkar joined NC State in January 2021, and is part of the university's National Science Foundation-funded ASSIST Center. The ASSIST Center's mission is to create self-powered, wearable health monitoring technologies.

Learn more about this year's honorees on the MIT Technology Review website here and in the July/August issue, which went live online June 30.

Founded in 1899, MIT Technology Review is an independent media company whose insight, analysis, and interviews explain the newest technologies and their commercial, social, and political impacts. MIT Technology Review's mission is to bring about better-informed and more conscious decisions about technology through authoritative, influential, and trustworthy journalism.

-shipman-

This press release was produced by North Carolina State University. The views expressed here are the author's own.

See original here:
North Carolina State University: Biochemical Sensor Researcher Makes MIT Technology Review's List Of Top Young Innovators - Patch.com

Dubocovich to receive ASPET’s Julius Axelrod Award in Pharmacology – UB Now: News and views for UB faculty and staff – University at Buffalo Reporter

Posted on January 15, 2022 by Danzig

The American Society for Pharmacology and Experimental Therapeutics (ASPET) has named Margarita L. Dubocovich, SUNY Distinguished Professor of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences at UB, the recipient of the 2022 Julius Axelrod Award in Pharmacology.

Dubocovich is receiving the award in recognition of her seminal work in understanding the physiological role of melatonin and its receptors on neuroendocrine function and circadian rhythms, and for her extraordinary contributions to the training of future pharmacologists, according to ASPET.

The Axelrod award was established in 1991 to honor the eminent American pharmacologist who shaped the fields of neuroscience, drug metabolism and biochemistry, and who served as a mentor for numerous world-renowned pharmacologists.

It is quite fitting that Dr. Dubocovich receives this honor, as her groundbreaking research on melatonin neuropharmacology builds upon the earlier work of Julius Axelrod, says Allison Brashear, vice president for health sciences and dean of the Jacobs School. I am pleased this award also recognizes her exceptional dedication to mentoring the next generation of pharmacologists.

Dubocovich is an international scholar on the brain hormone melatonin and its receptors. Her pioneering work has revealed melatonins impact on circadian rhythms, sleep disorders, depression, reproduction, body weight and torpor, an energy-conserving state similar to short-term hibernation.

It is a distinct privilege to receive an award honoring the memory of such an eminent Nobel laureate, pharmacologist, neuroscientist and mentor, whose scientific contributions still impact the discovery of medicines to treat psychiatric disorders today, Dubocovich says.

She first met Axelrod while she was completing her doctoral degree at the University of Buenos Aires in Argentina.

He visited a few years after hewon a share of the Nobel Prize in Physiology or Medicine in 1970, along with eminent pharmacologists Sir Bernard Katz and Ulf von Euler, for their discoverieson the release and reuptake of catecholamine neurotransmitters.

Our team, working on the modulation of catecholamine release by presynaptic receptors at the time, gathered for a conversation with Dr. Axelrod where we all had the opportunity to discuss our experiments and ask questions, Dubocovich recalls. This meeting shaped the course of my career and influences me to this day.

Dubocovich takes great pride in how her own work has contributed to the field of melatonin receptor pharmacology and physiology initiated by Axelrod.

Dr. Axelrods forthrightness and ability to define concise hypotheses were the foundation upon which he developed novel experimental methodologies and discoveries, she says. His philosophy of science was something which has remained with me throughout my career, and one that I hope to continue to impart onto future scientists in the legacy of Dr. Axelrod.

He emphasized the paramount importance of observation of biological effects over any complex analysis, Dubocovich adds. He used to say:If the effect is strong, then you do not need sophisticated analysisto recognize the experiment was successful to move forward with the project.

Building upon the early work of Axelrod, Dubocovich is credited with discovering and revolutionizing the field of functional melatonin receptors and pioneering the pharmacology of melatonin receptors agonists and antagonists.

Her seminal paper in the journal Nature in 1983 described the presynaptic regulation of dopamine release in the retina, and began her career-defining quest to understand melatonins role in physiological function and receptor pharmacology.

Dubocovich discovered luzindole, the first melatonin receptor antagonist, successfully demonstrating its antidepressant-like activity by blocking melatonin receptor types in mouse models.

She has continued to push the frontiers of neuropharmacology with studies of melatonin receptor-mediated effects on brain neurogenesis and drug design. Most recently, she broke new ground discovering that environmental agents impact the activity of melatonin receptors.

Dubocovich, who serves as senior associate dean for diversity and inclusion in the Jacobs School, is a passionate educator who has built culturally and intellectually diverse and academically inclusive communities of trainees, and instituted inaugural programs for trainee development at all levels.

After instituting the Collaborative Learning and Integrated Mentoring in the Biosciences (CLIMB) program at Northwestern University, she launched CLIMB programs at UB that now include professional development and mentoring programs for undergraduates, masters and doctoral students, postdoctoral fellows and junior faculty.

A National Institutes of Health (NIH) R25 grant has continuously funded her initiative for maximizing student development and has increased the number of underrepresented students in biomedical and behavioral research since 2012.

A dedicated mentor for research trainees, she has trained and provided research mentoring to 48 graduate and postdoctoral scholars. Her reputation as an outstanding research adviser is reflected in the fellowships that her trainees have received from NIH, the Pharmaceutical Manufacturers Association and others.

Her trainees currently hold academic positions and jobs in industry as pharmacologists, neuroscientists and toxicologists. Local and national mentoring awards have honored both her teaching and mentoring.

Dubocovich has been an ASPET member since 1983 and was named a fellow of the society in 2020.She was named a fellow of the American College of Neuropsychopharmacology in 2013.

Dubocovich says that over the years she had many opportunities to meet Axelrod at scientific conferences to listen to his talks and discuss their common interest in the pharmacology of melatonin receptors.

It is truly an honor to have had met him and to do what I can to carry his legacy forward, she says.

The award will be formally presented at the ASPET Business Meeting and Awards Presentation during the ASPET Annual Meeting at Experimental Biology 2022 on April 2 in Philadelphia.

The award includes invitations to deliver the Julius Axelrod Lecture and organize the Axelrod Symposium in 2023, and to deliver a less formal presentation at the 2022 annual dinner meeting of The Catecholamine Society, an international organization consisting of scientists interested in all aspects of catecholamine research, which was co-founded by Axelrod in 1969.

Go here to read the rest:
Dubocovich to receive ASPET's Julius Axelrod Award in Pharmacology - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter

Meta-Analysis Indicates Black Individuals With Prostate Cancer May Have Better Outcomes in Radiation Therapy Clinical Trials vs White Patients -…

Posted on January 15, 2022 by Danzig

Despite presenting with high-risk disease, Black patients with prostate cancer who enrolled on radiation therapy clinical trials were reported to have better rates of biochemical recurrence, distant metastases, and prostate cancerspecific mortality than White patients.

Although Black patients with prostate cancer who enrolled on radiation therapy clinical trials had more aggressive disease, they had better rates of biochemical recurrence, distant metastases, and prostate cancerspecific mortality vs White patients, suggesting that other factors such as access to care may be important in achieving equity, according to findings from a meta-analysis published in JAMA Network Open.1

Findings from the trial, which had a median follow up of 10.6 months, indicated that Black patients, although more likely to have high-risk disease features, were less likely to experience biochemical recurrence (sHR, 0.88; 95% CI, 0.58-0.91), distant metastases (sHR, 0.72; 95% CI, 0.58-0.91), or prostate cancerspecific mortality (sHR, 0.72; 95% CI, 0.54-0.97). Moreover, no significant differences in all-cause mortality were observed (HR, 0.99; 95% CI, 0.92-1.07). Even after adjusting, investigators reported that Black race continued to be significantly associated with improvements in biochemical recurrence (adjusted sHR, 0.79; 95% CI, 0.72-0.88; P <.001), distant metastases (adjust sHR, 0.69; 95% CI, 0.55-0.87; P = .002), and prostate cancerspecific mortality (adjusted sHR, 0.68; 95% CI, 0.50-0.93; P = .01).

These results do not suggest that there are no biological differences that might be associated with differences in prostate cancer incidence between racial groups, the study authors wrote. It is possible that the association with differential treatment response might be, at least in part, explained by differences in underlying biologic factors. Studies have reported distinct characteristics of prostate cancer in Black and White men at the genetic, epigenetic, and immunological level. These differences may have contributed to improved efficacy of multiple lines of systemic therapy in Black men compared with non-Black men with locally advanced or metastatic disease.

Investigators conducted a literature search in order to identify relevant, randomized studies that were conducted via NRG Oncology or Radiation Therapy Oncology Group from January 1, 1990, to December 31, 2010; this was significant as both groups have historically included a significant population of Black patients within its clinical research. The trial's primary end points were biochemical recurrence, distant metastases, and prostate cancerspecific mortality, with the key secondary end point being all-cause mortality.

Investigators included a total of 8814 patients, 18.5% of whom were Black and 81.5% of whom were White. The mean patient age was 69.1 years in the overall study cohort and most patients were considered to be low- (19.8%) and intermediate-risk (48.4%) with a smaller group of high-risk patients (31.8%).

Investigators observed that Black patients presented at a significantly lower median age compared with White patients (68 years vs 71 years). Additionally, the population was more likely to present with high-risk prostate cancer (38.2% vs 30.4%; P <.001), higher prostate-specific antigen levels (10.3 vs 8.4; P <.001), and Gleason scores ranging between 8 and 10 (16.3% vs 14.1%; P = .03) vs White patients.

The 10-year cumulative incidences of biochemical recurrence, distant metastases, and prostatecancer specific mortality in White and Black patients, respectively were 40.5% and 44.6% (P = .006), 8.4% and 11.6% (P = .005), and 4.5% and 6.4% (P = .03). The 10-year rate of all-cause mortality was comparable between White and Black patients (37.2% vs 36.6%; P = .50). Investigators clarified that prostate cancerspecific mortality rather than other cause mortality was responsible for the low rate of mortality events overall (6.5% vs 10.2%), in patients who were under 65 years of age (7.6% vs 14.9%), and older than 65 years (6.0% vs 9.2%). The same could be applied to patients with high-risk disease (6.4% vs 12.7%).

These results provide high-level evidence challenging the common belief that Black men who are diagnosed with prostate cancer will necessarily have a worse prognosis than White men, co-senior author Amar Kishan, MD, an associate professor and vice chair of clinical and translational research in the Department of Radiation Oncology at the University of California Los Angeles (UCLA) and a researcher at the UCLA Jonsson Comprehensive Cancer Center, said in a press release.2 This is especially important because an unfounded belief can inadvertently contribute to cancer injustice, leading to the use of more aggressive treatments than might be necessarypotentially reducing quality of lifeand diverting attention away from other important factors that can influence outcome, including access to more comprehensive healthcare.

Siler Ready to Meet Future as USM Readies for In-Person Graduation Ceremonies – Southern Miss Now

Posted on April 30, 2021 by Danzig

Thu, 04/29/2021 - 14:45pm | By: David Tisdale

Stay focused, but also find joy in the quest for knowledge and your degree.

Thats the advice graduating senior Camryn Siler has for those students coming behind her, as she plots her next moves after graduating from The University of Southern Mississippi (USM) next week. The university is preparing to hold multiple commencement ceremonies May 3-8, the first in-person graduation events since the Covid-19 pandemic.

You generally walk into your classes with the mindset of focusing on what you have to learn in order to pass, but take the time to really get into what your professor is teaching, said Siler, a native of Crestview, Florida. Any time youre enjoying something, it comes easier to you, so learn to make the best of what youre given.

And Siler has done just that during her time in Hattiesburg. A biological sciences major with an emphasis in biomedicine and minors in chemistry and biochemistry, she aspires to attend medical school. An Academic Excellence Scholar and a Jump Scholar, Siler earned the Scholastic Excellence Award on multiple occasions, Presidents List status and is a member of USMs National Society of Leadership Success.

Her USM roots run deep, as both of her parents and siblings attended the university, so I grew up around the campus, she said. Her father, Kenny Siler, helped lead the Golden Eagles mens basketball team to the 1987 National Invitation Tournament (NIT) championship.

Siler said being a student employee with USM Campus Recreation since she first started at USM was one of the first ways I became exposed to the USM culture, and it helped me get to know lots of people and make so many good friends. Other highlights of her USM experience include those where she learned something while having fun, too, including her job shadowing experience with Dr. Melissa Roberts, director of the USM Moffitt Student Health Center.

I learned [from Dr. Roberts] that being a doctor is more than poking and prodding people and filling out the paperwork to go with it, she said. It constitutes using your personality to make someone comfortable enough to even continue with their appointment, and gaining their trust in order for them to follow doctors orders.

She also praised her academic advisor, Dr. Janet Donaldson, for helping guide her through some challenges along the way, and also being there to help celebrate the high points.

Dr. D has been nothing but a blessing to me, Siler said.

Silers plans following graduation include pursuing a masters degree in biomedical sciences at the University of North Texas Health Science Center in Fort Worth, Texas, and then later applying to medical school; after medical school and residency, shed like to work in an outpatient center or hospital as an anesthesiologist.

Camryn was an absolute delight to have as one of my advisees, Dr. Donaldson said. She was always diligent about her work and such a pleasure to just talk to about school and her career ambitions. She is so sweet and so smart; I have no doubt she will be successful in whichever path life takes her.

In reflecting on the last year and the impacts of the Covid-19 pandemic on her academic experience and in all other aspects of life, Siler says the experience taught her to look within for motivation.

Im so used to having a huge support system that I forgot I have to want these things in life just as much as they want them for me, Siler said. So now Im very excited about the opportunity to be walking across that stage, and really couldnt imagine the ceremony being strictly virtual. We have all worked hard to make this happen and I think we all deserve a big congratulations for that.

Im also excited to be sharing this moment with last semesters graduates. The more the merrier!

For details about the USMs spring 2021 commencement ceremonies, visit https://www.usm.edu/registrar/commencement.php.

Here is the original post:
Siler Ready to Meet Future as USM Readies for In-Person Graduation Ceremonies - Southern Miss Now

What is biochemistry? – Biochemistry

Posted on June 7, 2021 by Danzig

Biochemistry is the branch of science that explores the chemical processes within and related to living organisms. It is a laboratory based science that brings together biology and chemistry. By using chemical knowledge and techniques, biochemists can understand and solve biological problems.

Biochemistry focuses on processes happening at a molecular level. It focuses on whats happening inside our cells, studying components like proteins, lipids and organelles. It also looks at how cells communicate with each other, for example during growth or fighting illness. Biochemists need to understand how the structure of a molecule relates to its function, allowing them to predict how molecules will interact.

Biochemistry covers a range of scientific disciplines, including genetics, microbiology, forensics, plant science and medicine. Because of its breadth, biochemistry is very important and advances in this field of science over the past 100 years have been staggering. Its a very exciting time to be part of this fascinating area of study.

To find out more about careers in biochemistry read our bookletsBiochemistry: the careers guideandNext Steps.

The life science community is a fast-paced, interactive network with global career opportunities at all levels. The Government recognizes the potential that developments in biochemistry and the life sciences have for contributing to national prosperity and for improving the quality of life of the population. Funding for research in these areas has been increasing dramatically in most countries, and the biotechnology industry is expanding rapidly.

The Biochemical Societyaims to inspire and engage people in the molecular biosciences. We offer study and careers advice toschool students,higher education studentsandteachersas well as carrying outpublic engagementevents.

The rest is here:
What is biochemistry? - Biochemistry

Brain gain: Medical researcher finds her way back to Erie thanks to new research facility – GoErie.com

Posted on February 20, 2021 by Danzig

Kara Murphy| For the Erie Times-News

Ashley Russell was stuck in traffic on Interstate 295 outsideBaltimore on a November day in 2019. She had finished her day as a post-doctoral research fellow at John Hopkins University and was talking to her parents in Erie on the phone to pass the time during the long drive home.

"It was just a soul-sucking hour-long commute each day," she said. "So I'd usually call my parents, and we'd talk."

2020: Behrend to serve as research partner

That day, her father had news he couldn't wait to share: A $26 million medical research center was coming to Erie. It meant up to 200 good jobs for the region, including two new faculty positions at Penn State Behrend. As Magee-WomenResearch Institute-Erie academic partner for the project, Behrend would create biomedical engineering and biochemistry/molecular biology academic programs.

Russell wanted to return to her hometown but didn't think her career would ever allow it.

"There was nowhere to do biomedical research in Erie," she said. "So I thought there was no way I'd ever live in Erie again."

Now there was not only an opportunity, but it was at Behrend, where she'd earned her undergraduate degree.

2019: $26 million medical research facility coming to Erie

She applied at her alma materand, in August, Russell returned, this timeto stay. Her title at Behrend is now assistant professor of biochemistry and molecular biology.

"Dr. Russell's research is a perfect fit for MWRI-Erie, and for Behrend's increased focus on biochemistry and molecular biology," said Ivor Knight, associate dean for research and graduate studies at Behrend.

Along with teaching, Russell and Jeremiah Keyes the other faculty member brought on at Behrend will lead studies in Behrend's new microbiology labs. Their work will support imaging and cell-growth testing related to MWRI-Erie research.

The larger of the two labs, a $1 million, 2,700-square-foot space in the Advanced Manufacturing and Innovation Center, will become the heart of an advanced imaging facility at Behrend and a resource for start-up companies and products that further Magee Women Research Institute-Erie's studies.

A second, smaller lab will be located in the Otto Behrend Science Building.

The pandemic delayed the new labs' completion, but Russell is hoping to start her first study at Behrend by mid-March. Her first study is looking for biomarkers of chronic stress during pregnancy that might indicate adverse pregnancy outcomes.

"A lot of this work will be done in collaboration with students, which is exciting because undergrad students bring a lot of energy and excitement to the table," she said. "We'll be training them to conduct experiments and how to collect and interpret data."

Knight said he believes Russell's studies will reach beyond Behrend's labs.

"Her study of chronic stress during pregnancy and the properties and behaviors of extracellular vesicles, particularly during the body's immune response, could, over the long term, influence the direction of research for MWRI-Erie, including clinical trials," he said.

Russell is excited about being part of the team building the program from the ground up at Behrend and what MWRI-Erie means for the future of scientific research in Erie.

Community leaders are hopeful as well.

Officials estimated in 2019 when announcing the project that $15 million in new federal research money will flow into Erie during the first five years and that research spending could reach $50 million by the tenth year.

"I believe this is just the beginning that this will open up a lot of opportunities to promote Erie as a biomedical hub for companies," Russell said.

And her commute now? It's 8 minutes.

Kara Murphy is a freelance writer in Erie and publisher of Macaroni Kid Erie. Contact her at murphy_kara@yahoo.com.

Go here to see the original:
Brain gain: Medical researcher finds her way back to Erie thanks to new research facility - GoErie.com

Select Page ::